IPR

Company

Board
Management
IPR
Collaborations

Pharma Holdings IPR

Pharma Holdings has secured broadly defined rights to our new class of cationic antimicrobial peptides– harnessing the essence of naturally occurring host defense molecules and designing around the potential disadvantages. We are also actively exploring new patent applications to prolong and expand our IPR.